CompletedPhase 3

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

United States101 participantsStarted 2013-06

Plain-language summary

The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.

Who can participate

Age range10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * positive bilateral conjunctival allergen challenge (CAC) reaction Exclusion Criteria: * known contraindications or sensitivities to the study medication or its components * any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters * use of disallowed medication during the period indicated prior to the enrollment or during the study

What they're measuring

Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-Dose)

Timeframe: 3, 5, 7 minutes post-CAC

Ocular Itching at Onset of Action (15 Minutes Post-Dose)

Timeframe: 3, 5, 7 minutes post-CAC

Conjunctival Redness at Duration of Action (8 Hours + 30 Minutes Post-Dose)

Timeframe: 7, 15, 20 minutes post-CAC

Conjunctival Redness at Onset of Action (15 Minutes Post-Dose)

Timeframe: 7, 15, 20 minutes post-CAC

Trial details

NCT IDNCT01881113

SponsorAciex Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-10

Results submitted2017-06-26

View on ClinicalTrials.gov More Allergic Conjunctivitis trials